imaging prostate cancer astellas
TRANSCRIPT
![Page 1: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/1.jpg)
Modern Imaging of Prostate Cancer: “Impact on Management Decision”
Mohamed Abdulla M.D.Prof. of Clinical Oncology
Cairo University
Dubai, 05/03/2016
![Page 2: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/2.jpg)
Speaker Disclosures:
Member of Advisory Board, Consultant, and Speaker for:• Amgen, Astellas, AstraZeneca, Hoffman la Roche, Janssen Cilag,
Merck Serono, Novartis, Pfizer• The content of this presentation does not relate to any product of a
commercial interest
![Page 3: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/3.jpg)
Prostate Cancer:Landscape of Disease:
Localized – Recurrent and/or Metastatic – CRPC – Death
Hormone Sensitive or Resistant
Asymptomatic or SymptomaticLoco
regio
nal T
hera
pies
ADT +
/- Ch
emot
hera
py2n
d Hor
mon
al M
anip
ulati
onCh
emot
hera
py –
Imm
unot
hera
py
Radi
oacti
ve Is
otop
es
![Page 4: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/4.jpg)
Prostate Cancer:Diagnostic Work up:
PSA
DRE+
TRUS
Gleason Score
Systemic Disease:• Isotopic Bone Scan• Computed Tomography• MRI• Others
Risk Stratification
Extra -Prostatic Disease
![Page 5: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/5.jpg)
Prostate Cancer:Diagnostic Work up: Unmet Needs:• DRE: Personal Variability.• Conventional Grey Scale US:
– Isoechoic & Anterior lesions.– Multifocal Disease, Heterogonous Texture.– Capsular Infiltration & Peri-prostatic Extension.– SV involvement.
• Computed Tomographic Scans:– Limited value for local disease extent.– Superior in Bone Metastases.
• Original MRI < 1 t:– Variable Sensitivity and Specificity.
• Isotopic Bone Scan:– No direct imaging of Bone Metastases.– Difficult to quantify burden of disease.
• PET – CT Scan:– 18FDG: Glycolytic Activity and not Osteoblastic activity.
![Page 6: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/6.jpg)
Clinical Scenario:• A 60-year-old postal employee presented for a free screening
exam.• DRE: equivocal with questionable asymmetric firmness.• PSA = 12 ng/ml• TRUS: 2 hypoechoic areas within the left side of peripheral
zone of one lobe of the gland Guided Biopsy.• 6 out of 12 biopsy cores had Gleason score of 7 (4 + 3)
adenocarcinoma.
![Page 7: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/7.jpg)
![Page 8: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/8.jpg)
![Page 9: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/9.jpg)
Recurrence Risk for Clinically Localized Prostate Cancer• Low Risk:
T1-T2a and Gleason score 2-6 and PSA < 10 ng/ml• Intermediate Risk:
T2b-T2c or Gleason score 7 or PSA 10-20• High Risk:
T3a or Gleason score 8-10 or PSA > 20• Very High Risk:
T3b-T4(locally advanced)
![Page 10: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/10.jpg)
Q:1- How Would You Stage This Patient??
1. CT scan abdomino-pelvis with contrast. 2. Multi-parametric MRI pelvis.3. Isotopic Bone Scan.4. Chest image.5. 1+3+46. 2+3+47. 2+4
![Page 11: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/11.jpg)
CASE (Cont…..)
• Patient had conventional chest imaging, CT-Scan of the abdomen and pelvis with contrast and Isotopic Bone Scanning.
• The patient discussed therapeutic options and elected radical prostatectomy.
• The final pathology report: positive capsule penetration, a positive surgical margin, and seminal vesicle invasion. Lymph nodes are negative.
• PSA decreases to 0.01ng/ml.
![Page 12: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/12.jpg)
What is the Proper Staging?1. Multiparametric MRI1. Diffusion Weighted Imaging (DWI).2. Prostate T2 Weighted Imaging.3. Dynamic Contrast Enhanced Images (DCE).4. Magnetic Resonance Spectroscopy Imaging (MRSI).
mpMRI is Mandatory of patients with Intermediate and High Risk Prostate Cancer & to confirm the validity of Active Surveillance.
![Page 13: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/13.jpg)
EUA Guidelines: Isotopic Bone Scanning is NOT Indicated in:1. Asymptomatic patients.2. Well to moderately differentiated disease.3. PSA < 20 ng/ml.
What is the Proper Staging?2. Isotopic Bone Scanning:
![Page 14: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/14.jpg)
Case Continuation:
• Patient received postoperative radiation therapy based on adverse pathologic features.
• Kept under follow up.• 2 years later, follow up PSA = 54 ng/ml while
patient was asymptomatic.
![Page 15: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/15.jpg)
Q2:
What are the imaging techniques to be requested?1. CT-Scan of abdomen and pelvis with contrast.2. Isotopic Bone Scan.3. Axial Skeleton MRI.4. 1+25. 1+3
![Page 16: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/16.jpg)
Imaging Recommendations:
• CT Scan & MRI.• Traditional Bone Scan is the standard except in
equivocal & suspecious negative cases Radiographs, MRI.
• PET-CT Scan FDG ?? (Bladder activity)• PET – CT Scan (Sodium Florid and Choline)
Uptodate, 2016
![Page 17: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/17.jpg)
Case Continuation:• Bone metastases (> 4 sites) and abdomino-pelvic nodal
disease (no visceral affection).• Started ADT & Docetaxel (PSA = 2 ng/ml)• 6 months following salvage therapy re-rise of PSA (85
ng/ml) Adding anti-androgen PSA = 3.5 ng/ml. Patient was asymptomatic.
• 4 months later, tender right shoulder (-ve in bone Scan, +ve in conventional radiograph palliative Rth). PSA 263 ng/ml. Serum Testosterone maintained castrate level metastatic CRPC. Patient is relatively asymptomatic.
![Page 18: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/18.jpg)
Q3:
What are the imaging procedures to be ordered?1. Body CT Scan with contrast.2. Isotopic Bone Scan.3. PET CT Scan.4. Axial Skeleton MRI5. 1+26. Non of the above.
![Page 19: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/19.jpg)
![Page 20: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/20.jpg)
Yes No Abstain
![Page 21: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/21.jpg)
TAKE HOME MESSAGE:
• Prostate cancer is a heterogeneous disease.• Assessment of disease extent is crucial.• mp MRI is mandatory in assessment.• Tc 99m, is the standard isotopic scan.• The value of Axial Skeleton MRI is more appreciated
in CRPC phase of disease.• Sodium Floride & Choline PET Scan are under
investigations.
![Page 22: Imaging prostate cancer astellas](https://reader034.vdocument.in/reader034/viewer/2022042604/5887e8f51a28ab7d5c8b4c63/html5/thumbnails/22.jpg)
Thank You